Trial Profile

A Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brogidirsen (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors NS Pharma

Most Recent Events

27 Mar 2024 Planned End Date changed from 28 Sep 2025 to 28 Nov 2025.
27 Mar 2024 Planned primary completion date changed from 28 Sep 2025 to 28 Nov 2025.
27 Mar 2024 Planned initiation date changed from 10 Aug 2023 to 22 Feb 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com